Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge
The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number …
respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number …
COVID-19-associated coagulopathy
M Franchini, G Marano, M Cruciani, C Mengoli, I Pati… - Diagnosis, 2020 - degruyter.com
Abstract Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently …
Anticoagulant treatment in COVID-19: a narrative review
V Carfora, G Spiniello, R Ricciolino, M Di Mauro… - Journal of thrombosis …, 2021 - Springer
Abstract The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family …
respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family …
Management of thrombotic complications in COVID-19: an update
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily …
syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily …
Pathogenesis and treatment strategies of COVID-19-related hypercoagulant and thrombotic complications
MA Haimei - Clinical and Applied Thrombosis/Hemostasis, 2020 - journals.sagepub.com
The new type of pneumonia caused by the severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) is endemic worldwide, and many countries cannot be spared, becoming a …
(SARS-CoV-2) is endemic worldwide, and many countries cannot be spared, becoming a …
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
Abstract The 2019 coronavirus disease (COVID-19) presents with a large variety of clinical
manifestations ranging from asymptomatic carrier state to severe respiratory distress …
manifestations ranging from asymptomatic carrier state to severe respiratory distress …
COVID-19 and coagulative axis: review of emerging aspects in a novel disease
M Boccia, L Aronne, B Celia, G Mazzeo… - … Archives for Chest …, 2020 - monaldi-archives.org
Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is
commonly complicated with coagulopathy and that disseminated intravascular coagulation …
commonly complicated with coagulopathy and that disseminated intravascular coagulation …
Anticoagulation in COVID-19: a systematic review, meta-analysis, and rapid guidance from Mayo Clinic
RD McBane II, VDT Roldan, AS Niven, RK Pruthi… - Mayo Clinic …, 2020 - Elsevier
A higher risk of thrombosis has been described as a prominent feature of coronavirus
disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis …
disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis …
Thromboembolic events and Covid-19
A Ribes, F Vardon-Bounes, V Mémier, M Poette… - Advances in biological …, 2020 - Elsevier
The novel Corona virus infection (Covid-19) first identified in China in December 2019 has
rapidly progressed in pandemic leading to significant mortality and unprecedented …
rapidly progressed in pandemic leading to significant mortality and unprecedented …
Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment
A Gąsecka, JA Borovac, RA Guerreiro… - … drugs and therapy, 2021 - Springer
Introduction Emerging evidence points to an association between severe clinical
presentation of COVID-19 and increased risk of thromboembolism. One-third of patients …
presentation of COVID-19 and increased risk of thromboembolism. One-third of patients …